- First phase of plant will be functional in 2021 and is part of Sami-Sabinsa Group’s strategy to expand existing ingredient growth and focus on new innovative products
Bengaluru, January 29, 2020: A pioneer and global leader in health science and nutraceuticals, Sami-Sabinsa Group today announced the launch of its new manufacturing facility at Pharma SEZ Industrial Area, Hassan, Karnataka. The first phase of the plant will house a 40,000 square metres world-class Active Nutraceutical Ingredients (ANI) manufacturing unit, with an annual capacity of 300 tons and will be functional by 2021. The new facility with a planned investment of Rs. 200 crore is part of the Sami-Sabinsa Group’s growth strategy.
Speaking at a press conference held in the city today, Dr. Muhammed Majeed,
Founder & Chairman, Sami-Sabinsa Group said, “World over, consumers are seeking alternatives to better health and looking for food and beverages that supply all their nutritional needs. As the pioneer and among the few Indian companies to have created a global market for patented formulations in the health space, we are committed to a research-oriented, science-based approach towards developing products that make lives healthier and better. The upcoming facility at Hassan, is a reinforcement of this commitment. The new unit when operational will play a pivotal role in boosting our exports further and help us to double our revenues. The first phase, once functional in 2021, will provide employment to around 400 qualified workforce in the fast-growing industrial region of Hassan”.
Mr. V.G Nair, Director and CEO, Sami-Sabinsa Group added, “Sami-Sabinsa’s new plant is designed to be world-class, meeting international standards & requirements and will house a high quality, environment-friendly Zero Liquid Discharge (ZLD) facility ensuring energy efficiency, responsible water management and biodiversity development. The ANI facility is 100% cGMP and regulatory compliant”.
The Hassan plant is Sami-Sabinsa Group’s sixth global manufacturing facility, in addition to its current units located in Peenya, Dobaspet, Kunigal, Hyderabad, Nelamangala and USA. When fully functional, the new plant will not only expand the Group’s overall manufacturing capacity but also strengthen Sami-Sabinsa Group’s ranking as among India’s foremost and largest global nutraceuticals major.
According to latest industry reports, the global market for nutraceuticals is set for robust growth. It is expected to reach $373 billion by 2025, growing at a CAGR of 7.5%, as per PMMI Business Intelligence report. The Indian nutraceuticals market has flourished to a $3 billion industry and is forecast to touch $8.1 billion by 2022.
About Sami-Sabinsa Group:
Sami-Sabinsa Group, a pioneer and global leader in health science and nutraceuticals, is a leading producer of nutraceuticals, cosmeceuticals, standardised herbal extracts, fine chemicals, specialty chemicals and probiotics. Founded in 1988 by Dr. Muhammed Majeed, an internationally acclaimed scientist turned entrepreneur in the field of Alternative Medicine, the Group has independent research divisions including Natural drugs, Phytochemistry, Synthetic Chemistry, Tissue Culture, Biotechnology, Analytical R&D, Biological Research, Microbiology and Formulations R&D, all of which coordinate in a synergistic work model to create products meeting international standards. Sami-Sabinsa Group under the visionary leadership of Dr. Majeed also pioneered the contract farming model deploying close to 40,000 acres of land, demonstrating its commitment to sustainable development. A team of 120 research scientists work tirelessly to discover and develop standardized natural extracts that render alternative therapy to emerging nutritional and health requirements across the globe. For more information visit samilabs.com.